Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 369

1.

The impact of syringe deregulation on sources of syringes for injection drug users: preliminary findings.

Deren S, Cleland CM, Fuller C, Kang SY, Des Jarlais DC, Vlahov D.

AIDS Behav. 2006 Nov;10(6):717-21.

PMID:
16642418
2.

Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York.

Fuller CM, Ahern J, Vadnai L, Coffin PO, Galea S, Factor SH, Vlahov D.

J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6 Suppl 2):S77-82.

PMID:
12489621
3.

Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program.

Pouget ER, Deren S, Fuller CM, Blaney S, McMahon JM, Kang SY, Tortu S, Andia JF, Des Jarlais DC, Vlahov D.

J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):471-7.

PMID:
16010172
4.

Syringe disposal among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program.

Cleland CM, Deren S, Fuller CM, Blaney S, McMahon JM, Tortu S, Des Jarlais DC, Vlahov D.

Health Educ Behav. 2007 Apr;34(2):390-403. Epub 2006 Jun 30. Erratum in: Health Educ Behav. 2007 Jun;34(3):551.

PMID:
16816027
5.

Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999.

Cotten-Oldenburg NU, Carr P, DeBoer JM, Collison EK, Novotny G.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):183-92.

PMID:
11404541
6.

Legal syringe purchases by injection drug users, Brooklyn and Queens, New York City, 2000-2001.

Des Jarlais DC, McKnight C, Friedmann P.

J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6 Suppl 2):S73-6.

PMID:
12489620
7.

Syringe distribution to injection drug users for prevention of HIV infection: opinions and practices of health care providers in New York City.

Coffin PO, Fuller C, Blaney S, Vadnai L, Miller S, Vlahov D.

Clin Infect Dis. 2004 Feb 1;38(3):438-41. Epub 2004 Jan 13.

PMID:
14727219
8.

A longitudinal study of syringe acquisition by Puerto Rican injection drug users in New York and Puerto Rico: implications for syringe exchange and distribution programs.

Finlinson HA, Oliver-Vélez D, Deren S, Cant JG, Colón HM, Robles RR, Kang SY, Andía JF.

Subst Use Misuse. 2006;41(9):1313-36.

PMID:
16861181
9.

Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities.

Bluthenthal RN, Malik MR, Grau LE, Singer M, Marshall P, Heimer R; Diffusion of Benefit through Syringe Exchange Study Team.

Addiction. 2004 Sep;99(9):1136-46.

PMID:
15317634
10.
11.

More pharmacists in high-risk neighborhoods of New York City support selling syringes to injection drug users.

Coffin PO, Ahern J, Dorris S, Stevenson L, Fuller C, Vlahov D.

J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6 Suppl 2):S62-7.

PMID:
12489618
12.

An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users.

Lurie P, Gorsky R, Jones TS, Shomphe L.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S126-32.

PMID:
9663635
13.

Strategies to improve access to sterile syringes for injection drug users.

Rich JD, Wolf FA, Macalino G.

AIDS Read. 2002 Dec;12(12):527-35. Review.

PMID:
12518719
14.

Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut.

Singer M, Baer HA, Scott G, Horowitz S, Weinstein B.

Public Health Rep. 1998 Jun;113 Suppl 1:81-9.

15.

As easy as ESAP. The New York State Expanded Syringe Access Demonstration Program.

Shotsky WJ, Cooper JG, Klein SJ.

Body Posit. 2003 Jan-Feb;16(1):15-7. No abstract available.

PMID:
12739507
16.

Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal.

Neaigus A, Zhao M, Gyarmathy VA, Cisek L, Friedman SR, Baxter RC.

J Urban Health. 2008 May;85(3):309-22. doi: 10.1007/s11524-008-9271-1. Epub 2008 Mar 14.

17.

Expanding access to sterile syringes through pharmacies: assessment of New York's Expanded Syringe Access Program.

Tesoriero JM, Battles HB, Klein SJ, Kaufman E, Birkhead GS.

J Am Pharm Assoc (2003). 2009 May-Jun;49(3):407-16. doi: 10.1331/JAPhA.2009.07127.

PMID:
19443321
18.

Explaining the relationship between race/ethnicity and pharmacy purchased syringes among injection drug users in New York City.

Fuller CM, Galea S, Blaney S, Ompad DC, Deren S, Des Jarlais D, Vlahov D.

Ethn Dis. 2004 Autumn;14(4):589-96.

PMID:
15724781
19.

Comparison of injection drug users accessing syringes from pharmacies, syringe exchange programs, and other syringe sources to inform targeted HIV prevention and intervention strategies.

Rudolph AE, Crawford ND, Ompad DC, Benjamin EO, Stern RJ, Fuller CM.

J Am Pharm Assoc (2003). 2010 Mar-Apr 1;50(2):140-7. doi: 10.1331/JAPhA.2010.09193.

20.

Feasibility of one-time use of sterile syringes: a study of active injection drug users in seven United States metropolitan areas.

Gleghorn AA, Wright-De Agüero L, Flynn C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S30-6.

PMID:
9663621

Supplemental Content

Support Center